Browse Articles

Discover research articles across all indexed journals

Incidence of mediastinal lymph node positivity in patients undergoing robotic transthoracic esophagectomy.

Journal of Clinical Oncology Kenneth Lee Meredith, Jamie Huston, Ravi Shridhar Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.379

379 Background: Esophageal cancer is increasing in incidence worldwide. Robotic approaches have quickly become mainstream due to the improved visualization and possible increase in nodal harvest. There remains significant debate on the utility of mediastinal lymph node dissection in esophageal cancer patients. We sought to analyze the incidence of mediastinal lymph node positivity and to evaluate its impact on survival in patients with esophageal cancer undergoing robotic assisted trans-thoracic esophagectomy (RATE). Methods: Utilizing a prospectively maintained esophageal database, we identified patients who were diagnosed with EC and underwent RATE between 2009-2024. We then identified patients with positive lymph nodes and stratified by location (celiac or mediastinal). Baseline univariate comparisons were made for continuous variables using both the Mann-Whitney U and Kruskal Wallis tests. Pearson’s Chi-square test was used to compare categorical variables. Survival analysis was performed via Kaplain-Meier method. Results: We identified 201 patients who underwent RATE with a median age of 70 (41-91). There were 160 (79.6%) males and 41 (20.4%) females. The mean BMI was 26.5 ± 5.5 and mean ASA score was 3.1 ± 0.6. Adenocarcinoma was the predominate histology at 162(80.6%). Locally advanced T3/T4 tumors were identified in 53 (26.4%) patients and 63(31.3%) had clinical node + disease. Neoadjuvant therapy was utilized in 159(79.1%) patients. The median lymph nodes resected 18 (14 – 22), and length of hospitalization 8 (7 – 11) days. The 30 and 90-day mortality were 2.2% and 2.6% respectively. R0 resections was performed in 200 (99.5%) of patients and the pathologic complete response rates were 42.1%. The incidence of mediastinal lymph node positivewas 6.3% vs 76.3% abdominal. There were 17.6% of patients that had both mediastinal and abdominal lymph nodes positive. The median survival was 23 months for abdominal LN+, 19.5 months for mediastinal LN+ p=0.23. Multivariate analysis revealed that age, neoadjuvant radiation, nodal positivity were predictors of survival. Conclusions: The incidence of mediastinal positive lymph nodes are much higher than previously reported. Perhaps the improved visualization and manipulation of tissue with robotic approaches have enhanced our ability to resect these nodes. Mediastinal lymph node positivity is a poor prognostic factor for survival in patients undergoing robotic esophagectomy. Given these findings, we would continue to support aggressive nodal resection in patients diagnosed with esophageal cancer.

The safety and short-term efficacy of neoadjuvant chemotherapy in elderly patients with resectable locally advanced esophageal squamous cell carcinoma.

Journal of Clinical Oncology Hiroshi Imazeki, Kazuhiro Shiraishi, Shun Yamamoto et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.433

433 Background: The standard treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) is neoadjuvant chemotherapy followed by surgery. However, the efficacy and safety of neoadjuvant chemotherapy for patients aged 76 or older have not been established because the JCOG1109 trial, which established the current standard of care, was limited to patients younger than 76 years. In our hospital, even patients aged 76 or older are treated with docetaxel, cisplatin, and 5-FU (DCF) or 5-FU / leucovorin, oxaliplatin, and docetaxel (FLOT), if the patient's general condition and organ function are maintained, but there have been few reports on the efficacy and safety of these therapies for elderly population. Methods: The subjects were 76 years old or older resectable LA-ESCC patients diagnosed as cT1N1-3M0, cT2-3N0-3M0, and cT1-3N0-3M1 (UICC-TNM 8th), who received at least one cycle of neoadjuvant DCF or FLOT in our institution from 2014 to 2023. Adverse events (CTCAE ver. 5.0) and histopathological responses were evaluated. Results: Patients who received neoadjuvant DCF (D group) and FLOT (F group) were 19 and 25, respectively. Patients background in the D / F group was as follows; median age 76 / 78 (years), male 84% / 64%, PS1 37% / 64%, clinical, T3 74% / 84%, clinical N1 32% / 52%, N2 47% / 32%, clinical stage III 53% / 64%, stage IVB 21% / 28%. Of the 19 patients in the D Group, 17 completed 3 cycles of treatment (completion rate 89%), 18 underwent surgery, including 2 patients who discontinued during the treatment (1 with disease progression and 1 with adverse event), and 1 underwent CRT. Of the 25 patients in the F group, 16 completed 4 cycles of treatment (completion rate 64%), 22 underwent surgery, including 8 patients who discontinued during the treatment (1 with disease progression, 6 with adverse events, and 1 with other), 2 underwent CRT, and 1 was placed on best supportive care. In the D and F groups, hematological toxicities were more common in the F group, especially grade 3 or more neutropenia was 26% / 96%, but febrile neutropenia was similar at 5% and 12%, respectively. Nonhematological toxicities were more common in the F group for all grades (nausea 42% / 64%, anorexia 63% / 80%, and fatigue 52% / 88%, while grade 3 or more toxicity was not significantly different from the D group (nausea 0% / 4%, anorexia 0% / 4%, and fatigue 5% / 4%). In the 18 patients of the D group and 22 patients of the F group who underwent surgery, R0 resection was performed in 94% / 95%, and pathological complete response (pCR) was 11% / 23%, respectively. Conclusions: Neoadjuvant triplet chemotherapy was well tolerated and resulted in high R0 resection rates and pathological responses even in patients aged 76 or older. Further investigation with long-term follow up is warranted to elucidate the clinical benefit of neoadjuvant chemotherapy for elderly LA-ESCC patients.

Does chemotherapy regimen matter for first-line immunochemotherapy in low programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC)? A systemic review and meta-analysis.

Journal of Clinical Oncology Jhe-Cyuan Guo, Pei-Shan Lin, Wen-Yi Shau et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.395

395 Background: Anti-programmed death 1 (PD-1) therapy plus chemotherapy has become standard first-line therapy for patients with high PD-L1-expressing advanced ESCC. The benefit for patients with low PD-L1-expressing ESCC remains debatable. Methods: Eligible studies were phase III trials investigating anti-PD-1/PD-L1 therapy plus chemotherapy (immunochemotherapy) vs chemotherapy as first-line therapy of advanced ESCC. Study-level pooled analyses of hazard ratios (HR) for progression-free survival (PFS) and overall survival (OS) with corresponding 95% confidence intervals (CI), were used to compare the different groups in random-effects model. PD-L1 expression levels with tumor proportion score (TPS) ≥ 1% vs < 1%, tumor area positivity (TAP) ≥ 10% vs < 10%, and combined positive score (CPS) ≥ 10 vs < 10 were collectively categorized as high vs low PD-L1 expression. The impact of two different chemotherapy regimens, TP (paclitaxel plus platinum) and PF (platinum pus fluoropyrimidine), stratified by PD-L1 expression levels, on the survival benefit of immunochemotherapy vs chemotherapy was investigated. Results: Eight randomized controlled trials including 4733 subjects were enrolled. Immunochemotherapy vs chemotherapy was associated with significantly improved PFS and OS irrespective of PD-L1 expression levels or chemotherapy regimens (Table). The PFS and OS benefits were more pronounced in high PD-L1 group than low PD-L1 group. In patients with high PD-L1 expression, the PFS and OS benefits were not significantly different between two chemotherapy regimen subgroups. However, in patients with low PD-L1 expression, the PFS benefit was more significant in TP subgroup than PF subgroup, and OS benefit trended to be in favor of TP subgroup. Conclusions: The addition of anti-PD-1/PD-L1 therapy to TP chemotherapy may associate with more significant survival benefit than to PF chemotherapy in advanced ESCC with low PD-L1 expression. Population PFS (immunochemotherapy vs chemotherapy) OS (immunochemotherapy vs chemotherapy) HR(95% CI) P value(subgroup differences) HR(95% CI) P value(subgroup differences) All patients 0.63 (0.57-0.69) 0.69 (0.64-0.74) High PD-L1 group 0.54 (0.49-0.60) P < 0.01 0.60 (0.53-0.67) P < 0.01 Low PD-L1 group 0.71 (0.62-0.81) 0.78 (0.70-0.87) TP group 0.56 (0.50-0.62) P < 0.01 0.66 (0.59-0.74) P = 0.32 PF group 0.68 (0.62-0.75) 0.72 (0.65-0.79) Among high PD-L1 patients TP subgroup 0.56 (0.45-0.69) P = 0.75 0.60 (0.46-0.78) P = 0.90 PF subgroup 0.53 (0.45-0.62) 0.59 (0.50-0.69) Among low PD-L1 patients TP subgroup 0.59 (0.48-0.74) P = 0.01 0.72 (0.55-0.93) P = 0.32 PF subgroup 0.82 (0.72-0.94) 0.84 (0.72-0.97)

Treatment sequences in patients with metastatic colorectal cancer in Japan: Real-world evidence of 1 <sup>st</sup> - to 5 <sup>th</sup> -line treatments.

Journal of Clinical Oncology Yoshinori Kagawa, Tsuyoshi Osaka, Toshiki Imamura et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.76

76 Background: The development of later-line drugs for metastatic colorectal cancer (mCRC) has expanded treatment options for systemic chemotherapy in patients with mCRC. However, few studies have investigated patients who received later-line treatment in a real-world setting, and available information on treatment sequences and transition rates from early- to later-line treatments is limited. Methods: This was a retrospective study using hospital administrative data collected by MDV (Medical Data Vision, Tokyo, Japan) from April 2008 through February 2023 in Japan. Treatment regimens were derived from standard treatments recommended in the Japanese guidelines. The study population was determined using an algorithm from a similar study previously conducted in Japan. Our analysis focused on patients who started CRC surgery or 1 st -line treatment after January 2017 to reflect recent late-line real-world practice. Transition rates from 1 st - to 5 th -line treatment were calculated, and treatment sequences were summarized using a Sankey diagram. Logistic regression was performed to identify the factors associated with the transition from 2 nd - to 3 rd -line treatment. Results: A total of 722,005 patients with a CRC diagnosis record were identified in the MDV database. Of these, 26,456 patients were included in the study population. The median age was 69 years and 61.4% of patients were male. The rates of transition to subsequent lines from 1 st to 5 th line ranged from 65.7% to 70.4% (1 st to 2 nd 68.3%; 2 nd to 3 rd 70.4%; 3 rd to 4 th 69.9%; 4 th to 5 th 65.7%). Among 8528 patients who received 2 nd -line treatment, ~70% of patients (6006) continued 3 rd -line treatment, and 30% of patients (2522) received best supportive care. Comparing these 2 patient groups, younger age (&lt;65 years, OR: 1.50, 95%CI: 1.35-1.67; p&lt;0.001) and longer treatment durations of 1 st (≥180 days, OR: 1.26, 95%CI: 1.14-1.39; p&lt;0.001) and 2 nd (≥120 days, OR: 1.67, 95%CI: 1.52-1.84; p&lt;0.001) lines were significant factors for 3 rd -line treatment continuation. Prior therapy with oxaliplatin or irinotecan plus molecular targeted drugs was also associated with a higher likelihood of proceeding to 3 rd -line treatment (OR: 1.42, 95%CI: 1.28-1.58; p&lt;0.001). Conclusions: In this study, ~70% of patients were able to transition to subsequent lines at the time of each line transition. However, 30% of patients were unable to continue treatment in real-world practice. To increase treatment continuation rates and maintain patient quality of life, new treatment options and further research are necessary to meet patients’ treatment needs, especially in the later-line treatment setting where unfavorable effects from previous treatments are accumulated.

Efficacy and safety of durvalumab and gemcitabine-based chemotherapy combined with or without lenvatinib in advanced biliary tract cancer.

Journal of Clinical Oncology Qi Ding, Haobin Yu, Yubei Sun et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.595

595 Background: Immunotherapy in combination with gemcitabine-based chemotherapy, has now become the standard first-line treatment for advanced biliary tract cancer (BTC). Some small-sample studies have shown that immune checkpoint inhibitors (ICIs), when used in combination with lenvatinib and chemotherapy as first-line therapy, exhibit high anti-tumor activity in BTC. Therefore, we conducted a retrospective study to assess the efficacy and safety of durvalumab and gemcitabine-based chemotherapy with or without lenvatinib, in combination for advanced BTC in the real world. Methods: Between January 2021 and September 2024, patients with advanced BTC who received either durvalumab combined with or without lenvatinib, along with gemcitabine-based chemotherapy, were enrolled in this study. The study endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Results: Thirty patients with advanced BTC were included in this study. Fourteen (46.7%) patients had received durvalumab combined with lenvatinib plus chemotherapy. For all the patients, the median OS was 9.5 months(95% CI: 4.98-14.02), and the median PFS was 5.9 months(95% CI: 4.56-7.24). ORR was 43.4% and DCR was 76.7%. Patients with lenvatinib treatment had a longer median PFS (7.1 vs. 4.6 months, P = 0.06) compared with the non-lenvatinib treatment group. However, the median OS was shorter in patients with lenvatinib treatment group (9.0 vs. 9.5 months, P = 0.915). ORR and DCR in patients with lenvatinib were 57.1% and 92.9%, respectively. However, in patients without lenvatinib treatment group, ORR and DCR were only 31.2% and 62.5%, respectively. All patients experienced adverse events (AEs), addition of lenvatinib does not increase the risk of AEs. The data is still being updated. Conclusions: Durvalumab and gemcitabine-based chemotherapy combined with or without lenvatinib has shown to be effective and safe in routine practice. Regarding lenvatinib, its addition has only improved the DCR, ORR, and PFS, but has not been able to prolong OS.

Real-world treatment patterns among U.S. adults with unresectable hepatocellular carcinoma (uHCC) eligible for locoregional therapy (LRT).

Journal of Clinical Oncology Shital Kamble, Karthik Ramakrishnan, Kathleen Hurwitz et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.547

547 Background: Treatment (tx) in uHCC has mostly relied on locoregional liver-directed tx, such as transarterial chemoembolization (TACE) or radioembolization (TARE), but recent pharmacotherapy advances have provided more tx options. This study aims to describe current real-world tx patterns and clinical outcomes of uHCC eligible for LRT. Methods: uHCC patients enrolled in TARGET-HCC (an ongoing, 5-year, longitudinal, observational cohort of HCC patients receiving usual care at academic and community sites in the U.S.), who initiated tx between 6/1/2020-6/1/2023 were included and followed until 12/31/2023 (data cutoff). Patients receiving curative HCC tx (ablation, resection, or transplant) or with metastatic HCC, portal vein involvement, or Child-Pugh-C liver disease at diagnosis (dx) were excluded. Patient and disease characteristics, and txs data were abstracted from electronic health records. Index tx was defined as first tx after dx, with a 30-day grace period for combination txs. Subsequent tx was defined as first tx after the grace period; for index systemic therapies, the subsequent tx differed from the index tx. Real-world progression-free survival (rwPFS) was defined as time from index tx to first event: radiological progression (including new lesions, extrahepatic involvement, vascular invasion, or &gt;20% increase in tumor burden from baseline), death, or hospice entry. Real-world time to progression (rwTTP) was defined as time from index tx to first radiological progression. Results: A total of 115 patients were included; mean age was 65.1 years and 77% were male. At dx, 41% of patients were BCLC B, 14% were non-metastatic BCLC C, and 38% were BCLC A with lesion &gt;5 cm, rapidly progressive disease, or contraindications to LRT. Tx initiation with TACE/TARE was common, either alone (n=59, 51%) or in combination with systemic tx (n=5, 4%). Among patients initiating systemic tx (n=46 ,40%), 30 received IO-IO (immuno-oncology) combinations, 12 received IO only, and 4 received a TKI only (tyrosine kinase inhibitor). Following index tx, 21 (18%) patients died receiving no subsequent tx and 27 (23%) were censored at data cutoff. Among those who received subsequent tx (n=67, 58%), there was heterogeneity in tx choice: TACE/TARE (n=32), systemic tx (n=16) other LRT (n=10), multimodal therapy (n=5), and transplant (n=4). We observed 60 progression events and 38 deaths corresponding to a median rwPFS and rwTTP of 7.9 (95% CI: 5.0, 13.3) months and 11.3 (95% CI: 6.7, 28.9) months, respectively. Conclusions: Our results showed high variability in management of uHCC eligible for LRT with TACE/TARE commonly utilized. Tx choice may be influenced by factors beyond staging criteria. Prognosis for uHCC eligible for LRT remains poor, and further research on adaptive, multimodal tx strategies is needed to inform tx guidelines and improve outcomes.

Is treatment delivery of perioperative FLOT therapy in locally advanced OGA associated with recurrence-free survival?

Journal of Clinical Oncology Keiji Sugiyama, Sacheen Kumar, M. Asif Chaudry et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.391

391 Background: Although perioperative FLOT therapy is a standard for locally advanced oesophagogastric adenocarcinoma (LA-OGA), completing all cycles, especially in the adjuvant chemotherapy (ACT) phase, is often challenging. This study examined the survival impact of treatment delivery in LA-OGA patients receiving FLOT therapy. Methods: 423 patients who underwent radical resection at The Royal Marsden Hospital from 2017 to 2023 were screened. Major inclusion criteria included patients with LA-OGA (cT2≤ and Nany or Tany and N+), treated with FLOT (at least one cycle of neoadjuvant chemotherapy) and radical resection, with an ECOG performance status of 0–2. Patients were divided into therapy incomplete (Tx Incomp, less than eight cycles of FLOT) and therapy (Tx comp) groups. We performed univariate and multivariate analyses, as well as propensity score matching (PSM) analysis, to evaluate whether treatment delivery was associated with recurrence-free survival (RFS) and overall survival (OS). Kaplan-Meier curves and restricted mean survival times (RMST) up to 36 months were used to evaluate the survival time. The primary endpoint was the 3-year RFS and OS rate. Results: Of the screened patients, 210 met the inclusion criteria, with 79 (38%) in the Tx Incomp and 131 (62%) in the Tx comp group, and 50 (24%) patients did not receive ACT. The median follow-up time was 26.5 months. The 3-year RFS and OS rates in the Tx Incomp and Tx comp groups after PSM were 54% vs 59% (p=0.14) (RMST difference: 4.04 months, p=0.09) and 58% vs 78% (p=0.04) (RMST difference: 6.15 months, p&lt;0.001), respectively. Multivariable analysis showed a significant impact of Tx comp on OS (HR 0.53, 95% CI: 0.32-0.88). In the subgroup of ypN-positive patients, a significant difference of RMST in OS rate was observed between those who started ACT and those who did not start ACT (RMST difference: 7.89 months, p=0.01), whereas no significant difference was found in the ypN-negative group (RMST difference: 0.65 months, p=0.75). Conclusions: This study suggests that completing FLOT therapy is associated with better OS. The impact of ACT might differ according to ypN stage.

A liquid biopsy analysis of exosomal miRNA to detect lymph node metastasis in early gastric cancer.

Journal of Clinical Oncology Masaaki Nishi, Yuma Wada, Chie Takasu et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.469

469 Background: Additional surgical resection is required to achieve a complete cure in patients with early gastric cancer (EGC) due to the potential risk for lymph node metastasis (LNM) after pathological analysis. However, LNM is estimated to occur in approximately 10% of patients with high-risk EGC. In this study, we investigated a blood-based liquid biopsy assay of exosomal miRNA for the noninvasive detection of LNM in patients with high-risk EGC. Methods: Two genome-wide miRNA expression profiling datasets (GSE164174 and TCGA) were analyzed to prioritize biomarkers in pretreatment plasma samples from clinical training and validation cohorts of GC patients. An integrated exosomal miRNA panel was developed and a risk stratification model combining the miRNA panel with clinical risk factors was established. Results: Using comprehensive expression profiling of public datasets, we identified a transcriptomic panel of four miRNAs (miR-34b, miR-130a, miR-375, and miR-627) that robustly identified patients with LNM [area under the curve (AUC) = 0.86, 95% confidence interval (CI) = 0.77-0.92]. We assessed panel performance in a training cohort (AUC=0.86, 95% CI=0.67-0.96) and validated it in an independent validation cohort (AUC=0.84, 95% CI=0.64-0.95). Our risk stratification model was more accurate than the panel and was an independent predictor of LNM identification (AUC=0.97). Conclusions: A novel noninvasive, liquid biopsy-based method for patients with EGC may predict those traditionally classified as high-risk patients with LNM who are unlikely to benefit from surgical resection.

XPO1 inhibition as a clinically viable strategy to enhance durability of response to KRAS <sup>G12D</sup> inhibitor in pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology Mohammed Najeeb Al Hallak, Husain Yar Khan, Amro Aboukameel et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.736

736 Background: The OFF State (GDP bound) KRASG 12D inhibitor MRTX1133 is currently being evaluated in pancreatic ductal adenocarcinoma (PDAC) patients. Nevertheless, as with other OFF state KRAS G12C inhibitors sotorasib and adagrasib, the KRAS G12D inhibitor may yield only a modest increase in disease-free survival due to emergence of drug resistance. This underscores the need to identify strategies that can enhance the efficacy of KRAS inhibitors in PDAC. Nuclear protein transport plays an important role in several pro-tumorigenic pathways and has been shown to be a therapeutic vulnerability in KRAS mutant cancers. XPO1 is the major nuclear exporter and plays a pivotal role in shuttling various critical tumor suppressors, genome surveillance proteins, and transcription factors out of the nucleus and is frequently overexpressed in various cancers, including PDAC. In this study, we employed a KRAS G12D inhibitor resistant model and evaluated its sensitivity to nuclear exporter protein inhibitor. Methods: We examined the cytotoxic and molecular effects of KRAS G12D inhibitor MRTX1133 in combination with nuclear transport inhibitor eltanexor in KRAS G12D inhibitor resistant models. The preclinical antitumor efficacy of the combination was evaluated in KRAS G12D mutant PDAC cell derived xenograft (CDX) subcutaneous and orthotopic models. Results: Eltanexor treatment reversed MRTX1133 resistance in vitro yielding suppressed proliferation of KRAS G12D mutant 2D and 3D cultures of PDAC cell lines and patient derived primary tumors cells. High throughput P-kinome analysis showed suppression of a larger repertoire of MAPK substrates in combination treatment compared to single agent group. Eltanexor and MRTX1133 combination led to reduction in protein expression of KRAS downstream effectors and cell cycle markers. Furthermore, a combined administration of eltanexor and MRTX1133 at sub-optimal doses resulted in remarkable tumor growth inhibition in multiple subcutaneous and orthotopic KRAS G12D mutant mice models. Moreover, eltanexor as a maintenance therapy also prevented tumor relapse indicating durability of response in PDAC. Conclusions: This is the first study demonstrating that nuclear transport inhibitors can overcome KRAS G12D inhibitor MRTX1133 resistance in PDAC cells. This study provides a rationale for combining MRTX1133 with eltanexor for the treatment of PDAC patients with KRAS G12D mutant tumors.

Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer.

Journal of Clinical Oncology Mohammad Zokaasadi, Wylie K Watlington, Divya Lakshmi Dayanidhi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.209

209 Background: Colorectal cancer (CRC) is the third most common cancer in adults in the United States. Given the relative rapid cell division in cancer cells compared to most normal cells, drugs targeting mitosis and other cell cycle checkpoints are of interest in CRC treatment. One multi-tasking protein in cell division is polo-like kinase 1 (plk1). Plk1 is a serine threonine kinase that is highly expressed during mitosis and involved in a variety of functions, including spindle assembly, chromosome segregation, G2/M transition, and cytokinesis. Encouragingly, its expression is also significantly higher in CRC compared to normal mucosa, which makes it an attractive cancer-specific target in CRC. In this study, we sought to evaluate the efficacy of plogosertib (CYC149462), a novel plk1 inhibitor, in a series of preclinical models of advanced CRC. Methods: Fourteen CRC patient-derived organoids (PDOs) were generated from patients who underwent biopsy or resection for their primary or metastatic CRC under an IRB approved protocol at Duke University. Diagnosis of CRC is confirmed in PDOs using H&amp;E and IHC. Subsequently, PDOs were treated with plogosertib in a range of concentrations from 256pM to 100µM. Drug screens were performed for standard of care agents 5FU, oxaliplatin, and SN38. Viability was assessed with Cell-Titer Glo (CTG) 72 hours after treatment. Using a matched PDX, mice were treated with vehicle or 40 mg/kg daily of plogosertib via oral gavage for 2 weeks, 5 days per week. Cell cycle analysis was performed by flow cytometry, and localization of DNA during mitosis was done by fluorescence staining. Results: CRC PDOs were more sensitive to plogosertib (CYC149462) than 5FU, and oxaliplatin, with significantly lower IC 50 values (518.86±377.47nM for plogosertib vs. 38.87±45.63µM for 5FU, and 37.78±39.61µM for oxaliplatin respectively (ANOVA, P &lt; 0.05). Subsequently, we validated our findings in vivo using a matched PDX in which plogosertib treatment led to significant tumor growth inhibition compared to vehicle (t-test, p &lt; 0.05) without serious adverse effects. Furthermore, we showed that plogosertib induces dysfunction in alignment of chromosomes and subsequent G2/M cell cycle arrest (p &lt; 0.05). Conclusions: Together, our study shows that pharmacological inhibition of Plk1 using plogosertib represents a promising therapeutic approach for advanced CRC.

Risk of residual tumor following removal of a malignant colorectal polyp with high-risk features.

Journal of Clinical Oncology Thikhamporn Tawantanakorn, Ayyuce Begum Bektas, Matthew Hill et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.136

136 Background: National guidelines recommend surgery when pathology analysis of a colorectal polyp reveals high-risk features: positive margin/piecemeal resection (PM/PR), lymphovascular/perineural invasion (LVI/PNI), poor differentiation (PD), or tumor budding (TB). However, some patients choose to avoid surgery, with its morbidity and quality-of-life implications, despite the risk of residual disease. Methods: This single-center cohort study determined the rates of luminal or lymph node disease and distant metastasis in patients who underwent surgery and patients who underwent observation following removal of a malignant colorectal polyp with high-risk features between 2015 and 2022. Results: Of 336 patients who underwent a polypectomy for a malignant polyp in the colon (n = 226) or rectum (n = 110), 312 had a PM/PR, 96 had LVI/PNI, 47 had PD, and 45 had TB; 208 patients (62%) underwent surgery, and 128 (38%) underwent observation. Patients with a malignant polyp in the rectum were more likely to undergo observation than patients with a malignant polyp in the colon (79 [72%] vs. 49 [22%] patients; P &lt; 0.01). In the surgery group, 19 patients (9%) had residual luminal disease, 39 patients (19%) had lymph node disease, and 5 patients (2%) had distant metastasis. In the observation group, disease was identified in 14 patients (11%): regrowth in the lumen, 7 patients (9%); regrowth in lymph nodes, 5 patients (6%); distant metastasis, 1 patient (1%); regrowth with distant metastasis, 1 patient (1%). The 12 cases of regrowth were salvaged: resection, 4 patients; local excision, 2 patients; chemoradiotherapy, 6 patients. Conclusions: The risk of residual disease following removal of a malignant colorectal polyp with high-risk features is considerable. Patients concerned about the morbidity of surgery and postsurgery quality of life should be counseled about this risk, as well as the availability of effective salvage options. High-risk features (HRF) Surgery(n = 208) Observation (n = 128) Luminal/LN disease at surgery(n = 51; 25%) Luminal/LN regrowth during observation(n = 12; 9.4%) Distant metastasis(n = 7; 2.1%) PM/PR (n = 312; 93%) 193 119 49 (25%) 12 (10%) 7 (2.2%) LVI/PNI (n = 96; 29%) 56 40 16 (29%) 3 (7.5%) 3 (3.1%) PD (n = 47; 14%) 33 14 11 (33%) 0 1 (2.1%) TB (n = 45; 13%) 20 25 5 (25%) 1 (4.0%) 1 (2.2%) 1 HRF (n = 215; 64%) 141 74 31 (22%) 8 (11%) 4 (1.9%) 2 HRF (n = 78; 23%) 39 39 11 (28%) 4 (10%) 1 (1.3%) 3 HRF (n = 35; 10%) 25 10 8 (32%) 0 2 (5.7%) 4 HRF (n = 6; 1.8%) 2 4 1 (50%) 0 0

Retrospective study evaluating the genomic landscape of anal squamous cell carcinoma using liquid biopsy.

Journal of Clinical Oncology Madison Conces, Sheila R. Solomon, J. Eva Selfridge et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.8

8 Background: Advanced-stage squamous cell carcinoma of the anus (aSCCA) is a rare malignancy. Diagnostic biopsies are often inadequate for tissue-based genomic profiling, thus genomic profiles are largely unexplored in this setting. We assessed liquid biopsy NGS results of aSCCA patients (pts) and described genomic profiles by age and sex. To our knowledge, we are the first to describe genetic alterations by liquid biopsy in this patient population. Methods: Pts with aSCCA who underwent circulating tumor DNA (ctDNA) NGS with Guardant360 assays from 2017 to 2024 were included. Frequency of alterations were assessed based on sex and age (18-49 years (yrs), ≥50 yrs). Co-occurrence patterns were assessed using cBioPortal. Demographics were extracted from test requisition forms. Statistical analyses via two sided t-tests were performed with significance defined as p&lt;0.05. Results: 646 pts with aSCCA had non-synonymous ctDNA alterations detected; 69.2% (N=447) were female and 30.8% (N=199) male. Median age was 66 yrs (32-94) with 9.9% (N=64) &lt;50 yrs and 90.1% (N=582) ≥50 yrs. Most frequently altered genes were PIK3CA (17.3%), TP53 (9.8%), ATM (7.8%), EGFR (4.3%), and BRCA2 (4.2%). More unique genes were altered in ≥50 yrs cohort [53 mutations, 38 genes with copy number amplification (CNA)] vs &lt;50 yrs cohort (30 mutations, 66 CNA). Most frequent genes altered in &lt;50 yrs cohort were TP53 (17.6%), PIK3CA (13.2%), EGFR (11.0%), APC (4.4%), and MET (4.4%). PIK3CA (16.7%), TP53 (12.2%), ATM (8.8%), BRCA2 (5.5%), and EGFR (3.4%) were most frequent in ≥50 yrs cohort. More genes were altered in females (64 mutations, 32 CNA) vs. males (56 mutations, 41 CNA). Most frequent alterations in females were PIK3CA E545K (3.4%), PIK3CA CNA (2.8%), PIK3CA E542K (1.9%), and ATM CNA (1.0%) vs in male pts being PIK3CA E545K (4.8%), PIK3CA CNA (3.3%), PIK3CA E542K (3.3%), EGFR CNA (1.6%), TERT promoter (1.0%). Overall, PIK3CA and TP53 alterations were mutually exclusive (odds ratio 0.43, p&lt;0.001). Conclusions: Liquid biopsy is feasible in patients with aSCCA. Most frequently detected alterations and CNAs were in PIK3CA and TP53 in aSCCA which is consistent with prior studies evaluating aSCCA tumor NGS in tissue-based assays. Alterations varied across age and sex. PIK3CA E545K and E542K alterations were detected frequently in this population and have on-label therapies for non-aSCCA indications which may be a source for clinical consideration in this cancer type in the future. This data illustrates the importance of liquid biopsy NGS to also screen for clinical trial enrollment in a disease which is poorly responsive to standard therapy. Additional research is warranted to further elucidate genomic profiles for clinical applications of this rare tumor.

Scalable Synthesis of 2D ErOCl with Sub‐meV Narrow Emissions at Telecom Band

Advanced Materials Panqi Huang, Youxuan Wu, Meng Gao et al. Feb 01, 2025 DOI: 10.1002/adma.202404698

AbstractVan der Waals (vdWs) materials are promising candidates for hetero‐integration with silicon photonics toward miniaturization and integration. VdWs materials like molybdenum telluride and black phosphorus, despite being prominent, exhibit air sensitivity, and their room temperature emissions can be significantly broadened by tens of meV. Here, a self‐encapsulation strategy is developed to scalably synthesize robust 2D vdWs ErOCl with sub‐meV narrow emissions at the telecom C‐band. Diverse 2D rare earth materials are also grown via chemical vapor deposition (TmOCl, YbOCl, HoOCl, DyOCl, SmOCl, NdOCl, TbOCl, GdOCl, EuOCl, and PrOCl), demonstrating the strategy's generalizability. The as‐grown ErOCl exhibits high crystalline quality and excellent ambient and thermal stability (300 °C). Photoluminescence analysis reveals a series of narrow emissions across the visible to near‐infrared spectrum. The ErOCl's emission at the telecom band is narrowest among 2D luminescent materials, and suitable for integrating with photonic chips. Temperature‐dependent photoluminescence spectra facilitate the understanding of emission mechanisms, analyzed using a crystal field perturbation model. Moreover, these emissions can be tuned by external magnetic fields. This research not only pioneers a novel strategy for synthesizing 2D rare earth materials but also paves the way for innovative building blocks in the realm of on‐chip optical communications.

Utility of circulating tumor DNA in patients with unresectable pancreatic cancer using a patient-specific panel: ARTEMIS-PC study.

Journal of Clinical Oncology Taro Shibuki, Hideaki Bando, Makoto Ueno et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.684

684 Background: Circulating tumor DNA (ctDNA) analysis has proven to be a highly accurate method for assessing treatment efficacy and detecting molecular residual disease (MRD) in cancer patients, outperforming tumor markers and imaging modalities. However, the ctDNA detection rate is reported to be low, and its utility remains unclear in pancreatic cancer (PC). We conducted the prospective “ARTEMIS-PC” study to evaluate the utility of a personalized, tumor-informed MRD assay in patients with unresectable PC. Methods: Eligible patients had histopathologically confirmed unresectable PC, were previously untreated, and had disease measurable per Response Evaluation Criteria in Solid Tumors v1.1. A patient-specific tumor-informed assay (Invitae Personalized Cancer Monitoring) was used for the detection of ctDNA. Blood samples were collected at structured pre- and post-systemic therapy timepoints. Results: A total of 99 patients were eligible for the ARTEMIS-PC study, and personalized panels were successfully created for 92 patients. The median age of patients was 70 years (range 45-81 years), with 43/92 being female. Thirty patients were stage III, and 62 stage IV. Median size of the primary tumor was 38 mm (range 13-100 mm). MRD positivity at enrollment was 88.0%, with 73.3% in stage III patients, and 95.2% in stage Ⅳ (p=0.007). During follow-up, ctDNA clearance was achieved in 33 patients (40.7%). ctDNA clearance was associated with a significantly higher objective response rate (61.5% vs. 17.6%, p=0.001) and disease control rate (100% vs. 64.7%, p=0.002) compared to those who did not achieve clearance. Patients who achieved ctDNA clearance had significantly longer progression-free survival (PFS) than those who did not (9.0 vs. 3.5 months, hazard ratio 0.2, p&lt;0.001). The predictive performance of select biomarkers (variant allele frequency [VAF], CEA, CA19-9) was evaluated using area under the curve (AUC) for treatment response and disease control. For disease control, VAF showed superior predictive performance with AUCs of 0.84 at enrollment and 0.97 at both Week 4 and Week 8, compared to CEA (AUCs: 0.65, 0.73, 0.60) and CA19-9 (AUCs: 0.51, 0.57, 0.56). The predictive performance for treatment response was lower than AUC 0.75 for any of the biomarkers. Among patients who were MRD negative before treatment or became negative during follow-up (n=44), 45.5% (n=20) subsequently turned MRD positive. Of these, disease progression was confirmed by CT in 14 patients. The median time from MRD turning positive to CT-confirmed progressive disease was 88.5 days (range: -28 to 385 days). Conclusions: ctDNA clearance is a useful predictor of improved objective response, disease control, and PFS, with VAF emerging as the more accurate biomarker for disease control, underscoring its potential utility in treatment monitoring in patients with unresectable PC. Clinical trial information: UMIN000043561 .

Comprehensive analysis of socioeconomic and clinical factors contributing to treatment delay in early-onset colorectal cancer.

Journal of Clinical Oncology Manasawee Tanariyakul, Jared David Acoba Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.32

32 Background: The prevalence of early-onset colorectal cancers (EOCRC) is rising globally. Disparities in social determinants of health can delay access to treatment and impacting outcomes. This study aims to analyze factors influencing time from diagnosis to treatment among EOCRC patients in a racially diverse population, considering tumor factors and sociodemographics. Methods: We analyzed EOCRC data from patients diagnosed between 2000 and 2022 at Queen’s Medical Center in Honolulu, Hawaii. Time from diagnosis to treatment for Asians, Whites, and Native Hawaiian or Other Pacific Islanders (NHOPI) was assessed using the Kaplan-Meier Method. Cox proportional hazards regression models were used to identify predictors, adjusting for clinical and pathological factors. Results: A total of 379 patients were analyzed. NHOPI were more like to be underinsured compared to Whites and Asians. In the unadjusted Cox model, underinsured/uninsured status, older age, unknown stage, left sided, and rectal locations were associated with delayed treatment. After adjustment, underinsured/uninsured status, older age, and rectal location remained significant predictors of delayed treatment. Conclusions: EOCRC patients with underinsured/uninsured status, age, and rectal tumor location are significantly associated with delayed in cancer treatment. While age was statistically significant, its clinical impact appears minimal. The need for a multidisplinary approach and additional preoperative staging in rectal cancer may explain treatment delays even after adjustment. Improving treatment accessibility and reducing delays, especially for underinsured EOCRC patients, is important. Univariate and multivariate analysis of time from diagnosis to treatment. Univariate Multivariate HR (95% CI) p-value HR (95% CI) p-value Insurance - - - - Private insurance - - - - Underinsured/Uninsured 0.692 (0.545-0.878) 0.003 0.706 (0.55-0.906) 0.006 Race White - - - - Asian 0.912 (0.696-1.195) 0.503 0.817 (0.619-1.077) 0.151 NHOPI 0.749 (0.548-1.025) 0.071 0.779 (0.562-1.08) 0.134 Age 0.978 (0.96-0.997) 0.021 0.968 (0.949-0.987) 0.001 Histopathology grade Grade 1&amp;2 - - - - Grade 3&amp;4 1.046 (0.798-1.371) 0.746 1.083 (0.813-1.441) 0.587 Stage 1 - - - - 2 1.022 (0.718-1.456) 0.902 1.071 (0.744-1.539) 0.713 3 1.227 (0.896-1.682) 0.203 1.387 (0.997-1.931) 0.052 4 0.964 (0.673-1.381) 0.842 1.039 (0.716-1.507) 0.842 Unknown 0.631 (0.406-0.981) 0.041 0.748 (0.473-1.182) 0.213 Sex Male - - - - Female 1.029 (0.836-1.267) 0.785 1.072 (0.868-1.325) 0.518 Microsatellite status Stable - - Unstable 1.074 (0.616-1.875) 0.8 Not done/Unknown 1.259 (1.004-1.577) 0.046 Location of Tumors Right - - - - Left 0.631 (0.468-0.851) 0.003 0.735 (0.535-1.011) 0.058 Rectal 0.43 (0.317-0.582) &lt;0.001 0.448 (0.327-0.613) &lt;0.001 NHOPI: Native Hawaiians and Other Pacific Islanders. HR: Hazard Ratio CI: Confidence Interval.

Multi-target stool-DNA test for colorectal cancer screening and effects on health and economic outcomes compared to blood-based tests: Influence of adherence.

Journal of Clinical Oncology Vahab Vahdat, Derek W. Ebner, Michael Dore et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.88

88 Background: There are an estimated 60 million individuals in the US who are not up-to-date with average-risk colorectal cancer (CRC) screening, as screening rates and adherence have remained stubbornly below the national target of 80%. Efforts are ongoing to improve CRC screening performance and participation, including the development of new blood-based tests. Despite high expectations for these tests, performance remains lower than other guideline-recommended strategies, particularly with respect to advanced precancerous lesion (APL) sensitivity. We conducted a simulation study of estimated clinical and economical outcomes for CRC screening with a blood-based test (at perfect adherence) compared to the multi-target stool-DNA (mt-sDNA) test (at published adherence rates). Methods: Utilizing CRC-AIM, a calibrated and validated microsimulation model, CRC screening outcomes were calculated for 1 million average-risk individuals screened between ages 45-75 years with triennial blood-based versus mt-sDNA testing. CRC and APL sensitivity and specificity inputs were derived from two large clinical validation studies for these screening modalities: ECLIPSE (NCT04136002) and DeeP-C (NCT01397747), respectively. To demonstrate the maximum benefits and burdens of blood-based screening, adherence to initial screening and follow-up colonoscopy after a positive blood test was modeled at 100%, while real-world adherence estimates of 65.6% were used for the mt-sDNA test. Outcomes of interest included life years-gained (LYG) and CRC cases missed by the blood-based test compared to the stool-based test, additional treatment costs imposed by theblood-based test, and additional CRC-related deaths per 1 million screened. Results: Compared to triennial screening with mt-sDNA at real-world adherence, blood-based screening at perfect adherence resulted in a higher number of incident (n=18,464) and fatal (n=6,483) CRC cases that would been avoided with the mt-sDNA test. Over a lifetime, screening with blood-based tests required 1,276,310 more tests (21% more) and 52,942 additional follow-up colonoscopies (7% more) compared to mt-sDNA screening. This increased testing burden did not generate additional benefits and instead reduced life-years gained by 67,645 per 1 million screened, resulting in an additional $1.6 billion in treatment costs compared to the mt-sDNA strategy. Conclusions: Data from this CRC-AIM modeling study show that even with perfect adherence, blood-based screening yields inferior clinical and economic benefits compared to mt-sDNA screening, due to suboptimal APL detection with the former test.

An OMV‐Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy

Advanced Materials Yichao Lu, Nana Ma, Keman Cheng et al. Feb 01, 2025 DOI: 10.1002/adma.202413392

Abstract Antigen‐presenting cells (APCs) process tumor vaccines and present tumor antigens as the first signals to T cells to activate anti‐tumor immunity, which process requires the assistance of co‐stimulatory second signals on APCs. The immune checkpoint programmed death ligand 1 (PD‐L1) not only mediates the immune escape of tumor cells but also acts as a co‐inhibitory second signal on APCs. The serious dysfunction of second signals due to the high expression of PD‐L1 on APCs in the tumor body results in the inefficiency of tumor vaccines. To overcome this challenge, a previously established Plug‐and‐Display tumor vaccine platform based on bacterial outer membrane vesicles (OMVs) is developed into an “Antigen Presentation Signal Enhancer” (APSE) by surface‐modifying PD‐L1 antibodies (αPD‐L1). While delivering tumor antigens, APSE can activate the expression of co‐stimulatory second signals in APCs due to the high immunogenicity of OMVs. More importantly, the surface‐modified αPD‐L1 binds to the co‐inhibitory signals PD‐L1, potentially restoring CD80 function and ensuring efficient co‐stimulatory second signals and activation of anti‐tumor immunity. The results reveal the importance of PD‐L1 blockage in the initiation process of anti‐tumor immunity, and the second signal modulation capability of APSE can expand the application potential of cancer vaccines to less immunogenic malignancies.

Social determinants of health and financial burden among patients with pancreatic cancer at a tertiary cancer center.

Journal of Clinical Oncology Khalid Jazieh, Minji K Lee, Kimberly O. Steinert et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.678

678 Background: Financial toxicity (FT) represents a challenge for cancer patients that impacts treatment decisions, patient satisfaction, and quality of life. Social determinants of health (SDoH) screening may predict who is at risk of FT and could potentially benefit from financial interventions. Methods: This is a retrospective study of all cancer patients presenting to Mayo Clinic sites between Sept 2023 – Jun 2024. Patients completed SDoH questionnaires and were given risk scores of Low Risk, Medium Risk, and High Risk for SDoH categories: Financial Strain Risk, Transportation Risk, and Food Insecurity Risk. Patient financial data including active debt amounts, insurance coverage, and financial aid were collected. Patients with pancreatic ductal adenocarcinoma (PDAC) were compared to those with pancreatic neuroendocrine tumors (PNET) and patients with other cancers (Others). Categorical variables were compared with Pearson's Chi-squared test, continuous variables with Kruskal-Wallis rank sum test. P values &lt; 0.05 were considered significant. Results: Data was obtained from 88,039 patients, 2,607 of whom had PDAC and 449 had PNET. Compared to PDAC patients, PNET patients and Others were more likely to have Medium/High risk scores for Financial Strain Risk (6% vs 6.5% and 8.5%, respectively) and Food Insecurity (1.7% vs 3.8% and 3.2%) (Table). There was no statistically significant difference in median medical debt and need of financial assistance between the groups. Among PDAC patients, there were differences in distributions among race, primary language spoken, and patient electronic record access depending on Financial Risk categories. African American patients had the greatest proportion of Medium/High risk (12.9%) compared to Asian (4.4%) and White (5.8%) patients (P&lt;0.001). Among patients with English as their primary language, 64.9% had Low Risk scores compared to 27.7% with other primary languages (P&lt;0.001). Patients with electronic record access were more likely to report High Risk scores (6.9%) compared to those without access (1.6%). Conclusions: Per patient responses collected, PDAC patients presenting to our center have lower risk of financial strain and similar medical debt levels compared to the remainder of cancer patients. Among PDAC patients, higher financial strain was experienced by non-whites (7.9% vs 5.8%). Diagnosis PDAC (N=2607) PNET (N=449) Other (N=84983) p value Current Financial Risk (Grouped) &lt; 0.001 - Low Risk 1662 (63.8%) 304 (67.7%) 59298 (69.8%) - Medium/High Risk 157 (6.0%) 29 (6.5%) 7209 (8.5%) - Unknown/Missing 788 (30.2%) 116 (25.8%) 18476 (21.7%) Food Insecurity Risk &lt; 0.001 - Low Risk 1764 (67.7%) 308 (68.6%) 63235 (74.4%) - Medium Risk 45 (1.7%) 17 (3.8%) 2703 (3.2%) - Unknown/Missing 798 (30.6%) 124 (27.6%) 19045 (22.4%) Median Active Debt in USD 1102.230 1020.010 1141.135 0.593

Can an alteration of the gut microbiome increase risk of gastrointestinal malignancies? Insights from the National Inpatient Sample.

Journal of Clinical Oncology Sweta Lohani, Suriya Baskar, Chaula Desai et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.841

841 Background: The gut microbiome is composed of trillions of microorganisms, inhabiting the lining of the gastrointestinal (GI) tract. The gut microbiome plays multiple roles in upholding human health including maintaining metabolism and regulating immune homeostasis. Dysregulation of the gut flora is known as gut dysbiosis. Studies have shown that gut dysbiosis is linked to the development of malignancies such as colorectal cancer. The purpose of this study is to assess the correlation between an altered gut flora and development of GI malignancies. Methods: The National Inpatient Sample was queried between 2016-2020 for all adult patients with altered gut flora, defined by history of gastrointestinal/bariatric surgeries, history of clostridium difficile infection, long-term antibiotic use, and inflammatory bowel disease. Rates of various cancers were compared between this cohort and all other patients utilizing chi-squared tests. Binary logistic regressions were utilized to calculate odds ratios of developing the various cancers, adjusted for age, sex, Charlson Comorbidity Index (CCI), and smoking status. Results: A total of 7,758,168 hospitalizations with altered gut flora were identified. Esophageal cancer (aOR 3.16, 95% CI 3.08 - 3.24) and colorectal cancer (aOR 3.15, 95% CI 3.11 - 3.18) were observed to have the highest odds of occurring in patients with altered gut flora. Gastric, hepatobiliary, pancreatic, and neuroendocrine cancers also all had significantly higher odds of occurring in patients with altered gut flora. Conclusions: Our study shows that conditions altering the gut flora are associated with increased odds of malignancies of the GI tract. This suggests that the gut microbiome may play an intricate role in regulation of tumor cell proliferation. Optimization of gut health and restoration of gut flora may prove beneficial to patients at high risk for malignancies of the GI tract. Altered Gut Flora (%) Intact Gut Flora (%) Adjusted Odds Ratio (CI) p-value Esophageal 0.4 0.1 3.16 (3.08 - 3.24) &lt;.001 Gastric 0.3 0.1 1.67 (1.64-1.69) &lt;.001 Colorectal 2.5 0.6 3.15 (3.11 - 3.18) &lt;.001 Hepatobiliary 0.4 0.3 1.04 (1.02 - 1.07) &lt;.001 Pancreatic 0.6 0.3 1.34 (1.31 - 1.37) &lt;.001 Neuroendocrine 0.2 0.1 1.38 (1.33 - 1.44) &lt;.001

Nationwide analysis of Medicare expenditure and utilization of EGFR inhibitors from 2018-2022.

Journal of Clinical Oncology Devang Namjoshi, Mansi Mehta, Vaibhavi Mukhtiar et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.112

112 Background: EGFR inhibitors are used extensively for treatment of metastatic colorectal cancer ranging from first line drugs in combination with chemotherapy to monotherapy for refractory disease. As we increasingly move towards targeted treatments for cancer, financial implications of these drugs must be taken into consideration. In this study we aim to analyze changes in Medicare spending for Cetuximab and Panitumumab to better understand the financial impact of these therapies. Methods: We obtained data from the publicly available Medicare Part D database from Centers for Medicare and Medicaid Services. Data on total spending, total claims, total beneficiaries, average spending per claim, and average spending per beneficiary was extracted from the database. We adjusted the data for 2018 for 2022 using a standard annual inflation rate. Percentage change was calculated using the adjusted data. Results: For Cetuximab, we saw a sharp increase in total spending by 38.77%, from $4,912,903.87 in 2018 to $6,811,781.05 in 2022. The number of claims rose by 31.96%, while the total number of beneficiaries saw a modest increase of 2.44%. Average spending per claim increased by 16.04%, and average spending per beneficiary grew by 49.44%. Panitumumab showed a similar rise in total spending by 43.23%, from $1,594,347.66 in 2018 to $2,283,142.83 in 2022. Claims increased by 25.42%, and beneficiaries grew by 47.83%. Average spending per claim increased by 25.97%, and average spending per beneficiary saw a substantial rise of 65.75%. Conclusions: Our results indicate a significant increase in the financial burden related to EGFR inhibitors. As we move away from chemotherapy and shift our focus to targeted therapies, it is imperative to explore generic alternatives and direct policy changes to ensure equitable access across various racial and socio-economic groups. These findings highlight the need for further research into healthcare policy reforms to ease the burden on our health system. Drug Year Total Spending ($) Total Claims Total Beneficiaries Avg Spending/Claim ($) Avg Spending/Beneficiary ($) Cetuximab 2018 4,912,903.87 551 123 8,072.80 36,163.51 2022 6,811,781.05 727 126 9,369.71 54,061.75 % Change 0.3877 0.3196 0.0244 0.1604 0.4944 Panitumumab 2018 1,594,347.66 5,955 184 242.72 30,714.91 2022 2,283,142.83 7,470 272 305.81 50,736.51 % Change 0.4323 0.2542 0.4783 0.2597 0.6575